Sanofi is assessing a possible acquisition of U.S. drugmaker Insmed as large pharmaceutical groups continue to look for growth through targeted biotech deals. The talks are still under review and ...
Insulet Corporation (PODD) slid 3.02% today as weakness followed recent amendments to its credit agreement and softer forward guidance, with sellers continuing to dominate. This move is reinforced ...
Insulet Corporation (PODD) dropped 4.04% after class action lawsuits were announced over alleged manufacturing control defects involving its Omnipod insulin delivery systems. The move is supported ...
Insulet Corporation (PODD) climbed 4.26% on renewed buying interest after multiple securities class action lawsuits were filed alleging misleading statements about product safety and manufacturing ...
Insulet (PODD) stock is trading at $157.8 after a modest move lower for the day. The price remains above its key short- and medium-term moving averages but stays below ...